Last reviewed · How we verify
Chronic Non-Allergic Rhinitis
Approved treatments
- Cutivate · Teva Pharm
- Verdeso · Padagis Us
- Flonase · GSK (GlaxoSmithKline)
- Arnuity Ellipta · Haleon Us Holdings
- Pulmicort Respules · AstraZeneca K.K.
- Nasonex · University of Alberta
- Rodinolone
- Flixotide · Mundipharma Research Limited
- Fluticason · Creighton University
- Aerospan Hfa
- Elocon · Merck & Co.
Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body. - MOMETASONE
12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic Non-Allergic Rhinitis patent landscape — cliff calendar, originator estates, attackable patents
- Chronic Non-Allergic Rhinitis treatment landscape brief
- Chronic Non-Allergic Rhinitis treatment updates RSS
Frequently asked questions about Chronic Non-Allergic Rhinitis
What drugs treat Chronic Non-Allergic Rhinitis?
Tracked treatments include Cutivate, Verdeso, Flonase, Arnuity Ellipta, Pulmicort Respules, Nasonex, Rodinolone, Flixotide.
What is the treatment for Chronic Non-Allergic Rhinitis?
Standard treatment for Chronic Non-Allergic Rhinitis includes Cutivate, Verdeso, Flonase, Arnuity Ellipta, Pulmicort Respules. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic Non-Allergic Rhinitis patent cliff · Chronic Non-Allergic Rhinitis CI report
- Treatment: Cutivate · Teva Pharm
- Treatment: Verdeso · Padagis Us
- Treatment: Flonase · GSK (GlaxoSmithKline)
- Treatment: Arnuity Ellipta · Haleon Us Holdings
- Treatment: Pulmicort Respules · AstraZeneca K.K.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing